Dompé Farmaceutici S.p.A and Dompé US Inc. announced that the National Organization for Rare Disorders (NORD) has awarded them the 2019 Industry Innovation Award for Oxervate. The Rare Impact Awards celebrate people, organizations, and innovators making exceptional contributions benefiting rare disease patients and caregivers.
Oxervate (cenegermin-bkbj) ophthalmic solution 0.002% was approved by the FDA in August 2018 as the first therapy specifically indicated to treat neurotrophic keratitis (NK), a rare and progressive eye disease that can impact the cornea, leading to scarring and reduced visual acuity.
“At NORD, we remain committed to increasing attention on rare diseases that impact day-to-day living for those who suffer from them,” Peter L. Saltonstall, President and CEO of NORD, said in a company news release. “We are proud to honor Dompé with an Industry Innovation Award and to thank them for the work they are doing on behalf of the rare disease community.”
Dompé supports the rare disease community through continued research and development activity in rare diseases, support of NORD’s RareCare program, and membership on NORD’s corporate council.
“Dompé is extremely proud of the development program that resulted in the FDA approval of Oxervate. In neurotrophic keratitis, we saw a devastating disease without any approved pharmacologic treatments targeting the root pathogenesis. We are honored to be able to offer this breakthrough therapy to patients who have been waiting for an effective and noninvasive option,” Sergio Dompé, Chairman of Dompé, said in the news release. “We would like to thank NORD for the Industry Innovation Award. We are inspired by our patients and their caregivers, and we remain committed to innovation for the benefit of patients facing even the rarest of conditions.”
The Rare Impact Awards will take place on Saturday, June 22 at Space Center Houston, the Official Visitor Center of NASA Johnson Space Center and a Smithsonian Affiliate.